Independent Panel of Renowned Pediatric Endocrinologists to Discuss Pediatric Growth Hormone Deficiency and the Therapeutic Landscape
PGHD, the Injectable Therapeutic Landscape, and Opportunity for an Oral Treatment Option
Virtual KOL Webinar
To register for the virtual KOL Event, please click through the link HERE
The event will feature the following renown thought leaders in the field of pediatric endocrinology:
Amrit Bhangoo, MD, Section Chair and Director of Research of the Division of Pediatric Endocrinologyat the Children’s Hospital of Orange County(CHOC) and Associate Professor of Pediatrics at the University of California, Irvine. Alejandro Diaz, MD, Chief of the Division of Pediatric Endocrinologyat Niclaus Children's Pediatric Specialistsin Miami, FL. Erica A. Eugster, MD, Professor of Pediatrics and Division Chief in Pediatric Endocrinology/ Diabetologyand Co-Director of the Pediatric Endocrine Fellowship Program at the Indiana University School of Medicine.
"Madhu" Misra, MD, MPH, Chief of Pediatric Endocrinology at Massachusetts General Hospital, Physician Investigator (Cl) of Neuroendocrine at Mass General Research Institute, Fritz Bradley Talbotand Nathan Bill Talbot Professorof Pediatrics at Harvard Medical School, and Pediatrician in the Pediatric Endocrinology Program and Diabetes Centerat Massachusetts General Hospital. Kent ReifschneiderMD, Associate Professor of Pediatrics in the Division of Endocrinologyand Children’s Specialty Groupat the Children's Hospital of The King'sDaughters (CHKD), Norfolk, VA.
The moderated panel discussion will be followed by a live question and answer session.
About PGHD and the Therapeutic Landscape
PGHD is the consequence of inadequate secretion of growth hormone from the pituitary gland in children resulting in low growth hormone (GH) in the body, insufficient production of downstream signaling molecules required for growth, and the subsequent lack of growth. The prevailing standard of care for PGHD consists of a daily injection of exogenous GH administered for approximately 7 years on average. Several once-weekly injectable GH therapies have recently been approved in the US and internationally to treat PGHD. LUM-201, also known as ibutamoren, is an orally administered investigational small molecule that promotes the secretion of GH from the pituitary gland and represents an opportunity for appropriately selected patients to avoid the daily or weekly injections involved with current or forthcoming therapies. LUM-201 has been observed to increase the amplitude of endogenous pulsatile GH secretion, which mimics the natural pattern of GH secretion.
Investor & Media Contact:
Lumos Pharma Investor Relations
Source: Lumos Pharma, Inc.